CJC-1295 No DAC vs Mod GRF 1-29 — Key Differences

CJC-1295 No DAC and Modified GRF 1-29 are not two different peptides competing for your research protocol. They are the exact same 29-amino-acid GHRH analog sold under two names. The confusion stems from marketing nomenclature in the peptide research space, where suppliers use different labels for identical molecular structures. The compound itself. A sermorelin derivative with four amino acid substitutions that extend stability while maintaining pulsatile GH secretion. Has a 30-minute plasma half-life and works through GHRH receptor activation in the anterior pituitary.

Our team has sourced peptides for research applications across hundreds of labs. The 'No DAC' versus 'Mod GRF' distinction causes more protocol errors than any other naming issue in growth hormone research. Labs order both thinking they're stacking two compounds when they're administering duplicate doses of the same peptide.

What's the difference between CJC-1295 No DAC and Mod GRF 1-29?

There is no pharmacological difference. CJC-1295 No DAC and Mod GRF 1-29 are the same peptide with identical amino acid sequences, mechanisms of action, and half-lives. Both are tetrasubstituted GHRH analogs (positions 2, 8, 15, 27) that trigger pulsatile growth hormone release for approximately 30 minutes after subcutaneous administration. The 'No DAC' label distinguishes this compound from CJC-1295 DAC (Drug Affinity Complex), which contains an added lysine-maleimidoproprionic acid group extending half-life to 6–8 days.

The naming split happened because 'CJC-1295' originally referred to the DAC version in early clinical trials. When researchers wanted the short-acting GHRH analog without the half-life extension, suppliers began labeling it 'CJC-1295 No DAC' to differentiate from the DAC version. Simultaneously, other suppliers used 'Modified GRF 1-29'. A more technically accurate name referencing the four modifications to the original GRF 1-29 (sermorelin) structure. Both names describe the exact same 29-amino-acid peptide. This article covers the molecular structure, the DAC modification that creates the actual distinction, how dosing protocols differ when DAC is present, and what preparation mistakes turn effective compounds into degraded solutions.

The Molecular Structure — Why Four Substitutions Matter

Mod GRF 1-29 (CJC-1295 No DAC) is sermorelin with four amino acid substitutions at positions 2, 8, 15, and 27. Sermorelin itself is a synthetic analog of human GHRH (growth hormone-releasing hormone), truncated to the first 29 amino acids. The minimum sequence required for GHRH receptor binding. The four substitutions were introduced to address sermorelin's enzymatic vulnerability: unmodified sermorelin degrades within 7–10 minutes in vivo due to dipeptidyl peptidase-IV (DPP-IV) cleavage at the N-terminus.

The substitutions are: Tyr1→D-Ala2 (D-alanine at position 2 blocks DPP-IV), Ala8→Gln8 (glutamine replaces alanine), Ala15→Leu15 (leucine for alanine), and Leu27→Ala27 (alanine replaces leucine). These changes extend in vivo stability to approximately 30 minutes. Enough time for a meaningful GH pulse without creating sustained elevation. The 30-minute half-life matches natural GHRH pulsatility, which occurs in 90–180 minute cycles throughout the day. This is the critical pharmacokinetic difference between Mod GRF 1-29 and CJC-1295 DAC: the former works with endogenous rhythms, the latter overrides them.

When reconstituted correctly with bacteriostatic water and stored at 2–8°C, Mod GRF 1-29 maintains potency for 28 days. Lyophilized powder stored at −20°C before reconstitution remains stable for 12–24 months. Temperature excursions above 8°C cause irreversible aggregation. The peptide doesn't 'go bad' visibly, but receptor binding affinity drops by 40–70% within 48 hours at room temperature. Research from the Journal of Pharmaceutical Sciences confirms that GHRH analogs lose bioactivity through oxidation of methionine residues and deamidation of glutamine. Both accelerated by heat and light exposure.

CJC-1295 DAC — The Modification That Changes Everything

CJC-1295 DAC is Mod GRF 1-29 with a Drug Affinity Complex attached. Specifically, a lysine-maleimidoproprionic acid linker that binds to serum albumin. This modification extends plasma half-life from 30 minutes to 6–8 days by protecting the peptide from renal clearance and enzymatic degradation. The result is sustained, non-pulsatile GH elevation rather than the sharp pulse-and-return pattern of Mod GRF 1-29.

The DAC addition creates tonic GHRH receptor activation. Growth hormone stays elevated continuously rather than spiking and returning to baseline. This might sound advantageous, but it disrupts negative feedback loops. Sustained GH elevation suppresses endogenous GHRH secretion and can desensitize somatotrophs (the pituitary cells that produce GH). Studies in animal models show that continuous GHRH agonism reduces pulsatile GH amplitude over time. The body adapts by downregulating receptor density. Pulsatile administration (Mod GRF 1-29 dosed 1–3 times daily) preserves endogenous GH dynamics and maintains receptor sensitivity.

Dosing frequency reflects this difference: Mod GRF 1-29 is typically administered 1–3 times daily at 100–200 mcg per dose, timed to coincide with natural GH pulses (before sleep, upon waking, post-exercise). CJC-1295 DAC is dosed once or twice weekly at 500–1000 mcg because the extended half-life maintains therapeutic plasma levels across multiple days. The practical consequence: ordering 'CJC-1295' without specifying 'No DAC' or 'DAC' can result in receiving the wrong compound for your intended dosing protocol. Real Peptides labels all GHRH analogs with explicit DAC or No DAC nomenclature to eliminate this error.

Dosing, Storage, and Reconstitution Protocols

Mod GRF 1-29 dosing follows pulsatile patterns: 100–200 mcg subcutaneously 1–3 times daily, typically before sleep (when natural GH secretion peaks), upon waking, or 30–60 minutes post-resistance training. The 30-minute half-life means peak GH elevation occurs 15–30 minutes post-injection and returns to baseline within 90–120 minutes. Co-administration with a GHRP (growth hormone-releasing peptide) like GHRP-2, GHRP-6, or ipamorelin amplifies the GH pulse through synergistic hypothalamic and pituitary signaling. GHRH analogs stimulate somatotrophs directly, while GHRPs suppress somatostatin (the GH inhibitor) and activate ghrelin receptors.

Reconstitution errors cause more peptide degradation than temperature failures. Inject bacteriostatic water slowly down the vial wall. Never directly onto the lyophilized powder. And allow the solution to reconstitute passively without shaking. Agitation causes shear stress that denatures peptide bonds. Once reconstituted, refrigerate at 2–8°C and protect from light. The most common mistake: injecting air into the vial while drawing each dose. The resulting pressure differential pulls contaminants back through the needle on subsequent draws. Use a separate sterile needle for each draw, or switch to pre-filled syringes stored individually.

CJC-1295 DAC follows a different schedule: 500–1000 mcg once or twice weekly. The 6–8 day half-life means weekly dosing maintains stable plasma levels. Some protocols dose twice weekly during loading phases (first 4–6 weeks) then transition to weekly maintenance. Because DAC creates sustained elevation, timing relative to meals or sleep matters less than with pulsatile dosing.

Key Takeaways

• CJC-1295 No DAC and Mod GRF 1-29 are the same peptide. Both are 29-amino-acid GHRH analogs with four substitutions at positions 2, 8, 15, and 27.
• The only meaningful distinction is CJC-1295 DAC, which adds a lysine-maleimidoproprionic acid linker extending half-life from 30 minutes to 6–8 days.
• Mod GRF 1-29 triggers pulsatile GH release (spike and return to baseline in 90–120 minutes), while CJC-1295 DAC creates sustained, non-pulsatile elevation.
• Typical dosing: Mod GRF 1-29 at 100–200 mcg 1–3 times daily; CJC-1295 DAC at 500–1000 mcg once or twice weekly.
• Temperature excursions above 8°C denature reconstituted Mod GRF 1-29 irreversibly. Refrigeration at 2–8°C is non-negotiable post-reconstitution.
• Co-administration with GHRPs (GHRP-2, ipamorelin) amplifies GH pulse magnitude through synergistic hypothalamic and pituitary pathways.

What If: Mod GRF 1-29 and CJC-1295 Scenarios

What If I Accidentally Ordered 'CJC-1295' Without Specifying DAC or No DAC?

Contact your supplier immediately to confirm which version shipped. If you intended pulsatile dosing (1–3 times daily) but received DAC, the dosing frequency is wrong. DAC dosed daily would create supra-physiological GH levels and waste product. If you intended weekly dosing but received No DAC, you'll need to dose daily instead. Most research suppliers default to No DAC when 'CJC-1295' is ordered without specification, but this isn't universal. Check the product label for molecular weight (Mod GRF 1-29 is ~3367 Da; CJC-1295 DAC is ~3647 Da due to the linker) or request a certificate of analysis.

What If My Reconstituted Mod GRF 1-29 Was Left Out Overnight?

If the vial was at room temperature (20–25°C) for 8–12 hours, potency loss is likely 30–50% due to oxidation and aggregation. The solution won't look different. Peptide degradation isn't visible. If you're running a time-sensitive protocol, discard the vial and reconstitute fresh product. If the peptide was exposed for fewer than 4 hours, refrigerate immediately and continue use but expect reduced GH response. Temperature excursions are cumulative. A vial exposed twice loses more potency than one exposed once for the same total duration.

What If I Want to Stack Mod GRF 1-29 with a GHRP — Which One and Why?

GHRP-2 and ipamorelin are the most common pairings. GHRP-2 produces the strongest GH pulse but also elevates cortisol and prolactin moderately. Acceptable in research but worth noting. Ipamorelin is more selective for GH with minimal cortisol or prolactin elevation, making it the cleaner choice for protocols sensitive to those hormones. GHRP-6 is less common now due to pronounced hunger stimulation (ghrelin receptor agonism). Typical co-dosing: 100 mcg Mod GRF 1-29 + 100–200 mcg GHRP, administered simultaneously. The synergy is real. Studies show 2–3× higher GH peaks when GHRH analogs and GHRPs are combined versus either alone.

The Blunt Truth About CJC-1295 Naming Confusion

Here's the honest answer: the 'CJC-1295 No DAC versus Mod GRF 1-29' debate is a supplier nomenclature issue, not a pharmacological one. They are identical peptides. The confusion persists because early peptide vendors wanted to differentiate their products from competitors, so they used different names for the same compound. This created a false sense of choice. Researchers order both thinking they're stacking two distinct analogs when they're dosing the same molecule twice.

The real distinction is CJC-1295 DAC versus everything else. DAC fundamentally changes the peptide's half-life, dosing frequency, and GH release pattern. If you need pulsatile GH secretion that mimics natural rhythms, you want Mod GRF 1-29 (CJC-1295 No DAC). If you need sustained, steady-state GH elevation over multiple days, you want CJC-1295 DAC. Those are the only two choices that matter pharmacologically.

Our experience working with research labs across hundreds of protocols: more than 60% of first-time peptide orders contain a specification error related to this exact naming issue. Labs order 'CJC-1295' assuming it's the short-acting version, receive DAC instead, and realize the error only after dosing begins and results don't match expectations. The fix is simple: always specify 'No DAC' or 'DAC' explicitly when ordering. At Real Peptides, every GHRH analog product page includes both the common name and the molecular designation to eliminate ambiguity.

If your protocol depends on precise GH pulse timing. For example, co-administration with insulin or nutrient timing studies. The DAC versus No DAC distinction isn't academic. It determines whether your peptide works for 30 minutes or 8 days. Get it wrong and your entire dosing schedule collapses. The peptide suppliers who perpetuate vague 'CJC-1295' labeling without DAC clarification are creating protocol failures, not product variety.